dc.contributor.author | Vargha, D | |
dc.contributor.author | Greene, J | |
dc.date.accessioned | 2017-11-29T16:18:14Z | |
dc.date.issued | 2017-04-29 | |
dc.description.abstract | More so than most of its European neighbours, Spain at the turn of the 21st century thought it had relegated diphtheria to the past: the country had not seen a case of diphtheria since 1986. Not, that is, until a 6-year old boy was diagnosed with the disease in May, 2015. Although diphtheria has been a curable disease since the development of diphtheria antitoxin (DAT) in the 1890s and its widespread manufacture in the early 20th century, scarcely a month after his diagnosis, the child succumbed to this disease thought to have been largely tamed by modern medical science. | en_GB |
dc.identifier.citation | Vol. 389 (10080), pp. 1690–1691 | en_GB |
dc.identifier.doi | 10.1016/S0140-6736(17)31069-3 | |
dc.identifier.uri | http://hdl.handle.net/10871/30505 | |
dc.language.iso | en | en_GB |
dc.publisher | Elsevier | en_GB |
dc.rights | © 2017 Elsevier Ltd. All rights reserved. | en_GB |
dc.title | Grey-market medicines: Diphtheria antitoxin and the decay of biomedical infrastructure | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2017-11-29T16:18:14Z | |
dc.identifier.issn | 0140-6736 | |
dc.description | This is the author accepted manuscript. The final version is available from Elsevier via the DOI in this record. | en_GB |
dc.identifier.journal | Lancet | en_GB |